Publications

Hogan Lovells Publications

Pharma companies may benefit from proposed patent law changes in China; public comment invited

On 4 January, China's National People's Congress (NPC) released draft amendments to the Chinese Patent Law, proposing expanded and enhanced protections that may provide real benefits to...

Hogan Lovells Publications

Individualized therapies and the future of drug regulation

Hogan Lovells Publications

Regulatory Insights for Life Sciences and Health Care Investments: Cell and Gene Therapies

Investing in the life sciences industry without an understanding of the key regulatory factors that could determine a product's success or failure could cost you millions of dollars.

Hogan Lovells Publications

President signs 2018 Farm Bill with hemp reforms – implications for regulatory oversight of hemp-derived products including cannabidiol (CBD)

On December 20, 2018, President Donald Trump signed the Agricultural Improvement Act of 2018 (the 2018 Farm Bill) into law.

Media Mention

Sources: CBO Score Of OTC Monograph Could Be Sign Of Movement

David Horowitz discussed the Congressional Budget Office's (CBO) score of the U.S. Senate's over-the-counter monograph reform bill in the Inside Health Policy article titled "Sources: CBO...

Hogan Lovells Publications

Welcome to the real world: FDA issues long-awaited framework for evaluating the potential use of real-world evidence to support regulatory decisions for drugs and biologics

On December 6, the Food and Drug Administration (FDA) published a framework for its Real-World Evidence (RWE) Program to strategically leverage information gathered from real-world...

Hogan Lovells Publications

Regulatory Insights for Life Sciences and Health Care Investments: Regulatory changes in Europe

Investing in the life sciences industry without an understanding of the key regulatory factors that could determine a product’s success or failure could cost you millions of dollars.

;
Loading data